non-small-cell lung cancer (nonsquamous cell lung cancer)
Conditions
Interventions
Cisplatin (60mg/m2) and bevacizumab (15mg/kg) is administered on day 1, and S-1 (80mg/m2/day) is administered from day 1 to day 14
Sponsors
Gunma University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Histologically and/or cytologically proven nonsquamous NSCLC; patients with unresectable stage IIIB or IV, no previous chemotherapy or radiotherapy; a performance status of 0-1 on the Eastern Cooperative Oncology Group; adequate bone marrow reserve (leukocyte ≥4000/mm3,neutrophil≥2000/mm3, platelet ≥100,000/mm3,hemoglobin≥9g/dL; normal liver function (total serum bilirubin≤1.5mg/dL, and aspartate transaminase (AST), alanine transaminase (ALT) less than twice the upper limit of the normal range) and normal renal function (creatinine clearance≥60mL/min);PaO2≥60 torr or SpO2≥90%; proteinuria≤+1, INR≤1.5; a life expectancy of 12 weeks or more;written informed consent should be obtained from all patients.
Exclusion criteria
Exclusion criteria: squamous cell (adenosquamous cell) lung cancer; Patients with a history of serious drug allergy, hemoptysis, thrombosis, concomitant malignancy, central nervous system metastases, active infectious diseases or other serious medical problems;hemorrhagic diathesis or coagulopathy; therapeutic anticoagulation; regular use of aspirin (>325 mg per day), nonsteroidal antiinflammatory agents, or other agents known to inhibit platelet function;use of steroid or flucytosine;pregnancy ;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival, progression-free survival, time to treatment failure, safety | — |
Countries
Japan
Contacts
Public ContactNoriaki Sunaga
Gunma University Hospital Department of Respiratory Medicine
Outcome results
None listed